The Pharma Letter |
Global asthma market to hit $18 billion by 2021 boosted by biologics
The Pharma Letter Natasha Spiller, an analyst at Datamonitor Healthcare said: “Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated, despite the use of inhaled corticosteroids and long-acting beta 2 … |
View full post on asthma – Google News